ATUM Selects Gavin Barnard, Ph.D. as New Chief Scientific Officer to Lead Innovation

ATUM Appoints Industry Veteran Gavin Barnard, Ph.D. as Chief Scientific Officer

ATUM has officially announced the appointment of Dr. Gavin Barnard as the new Chief Scientific Officer (CSO). With a remarkable career spanning over two decades in the biopharmaceutical sector, Dr. Barnard is set to lead ATUM's scientific strategy and technology initiatives, focusing on expediting development timelines for biologics.

Dr. Barnard brings a wealth of experience from his previous senior leadership roles at industry powerhouses such as Genentech and Eli Lilly and Company. His expertise in advancing biotherapeutics from initial discovery stages through to clinical manufacturing positions him perfectly to lead ATUM's scientific pursuits. Under his leadership, the company aims to enhance its solid foundation in integrated service offerings.

Key Responsibilities and Goals

As the newly appointed CSO, Dr. Barnard will oversee several critical areas that are pivotal to ATUM's operations:

1. Hit-to-Lead Services: A key focus will be optimizing drug candidate assessments via in silico modeling, small-scale expressions, and enhanced analytics facilitated through artificial intelligence. This approach is expected to streamline decision-making processes in drug development.

2. Cell Line Development: Dr. Barnard will maintain the momentum of ATUM's innovative Leap-In Transposase technology, which has already led to the filing of over 50 Investigational New Drug (IND) applications. This technology is integral to developing robust and scalable cell lines that are essential for biopharmaceutical production.

3. Complex Modalities Roadmap: The strategic approach also includes expanding ATUM's service offerings, particularly in the development of complex modalities such as multispecific antibodies and antibody-drug conjugates (ADCs). These cutting-edge therapeutic options are crucial for addressing unmet medical needs.

A Vision for Collaboration

Expressing his excitement about joining ATUM, Dr. Barnard stated, “I have seen firsthand the transformative power of ATUM's technology. Its ability to address the broader challenges in the industry is remarkable. I look forward to collaborating with this world-class team to support our clients in bringing their innovative therapies to clinical settings.”

CEO of ATUM, Dr. Jeremy Minshull, welcomed Dr. Barnard, stating, “Gavin's extensive technical knowledge and industry experience will play a significant role in our journey to innovate and deliver impactful solutions for our clients.” This statement reflects the company’s optimism about the future direction under Dr. Barnard's leadership.

About ATUM

ATUM is a pioneering biotechnology contract research organization, focusing on services related to gene design, protein engineering, and cell line development. By leveraging advanced machine learning techniques, synthetic biology, and proprietary expression technologies, the company aims to transform digital sequences into real-world clinical applications. Headquartered in Newark, California, ATUM continues to enhance its global impact by offering tailored solutions that meet the diverse needs of its partners.

For more information about ATUM and its services, visit ATUM’s website.